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Abstract 
Background: Subclinical Plasmodium parasitaemia is an important reservoir for the transmission and persistence of 
malaria, particularly in low transmission areas.
Methods: Using ultrasensitive quantitative PCR (uPCR) for the detection of parasitaemia, the entire population of 
three Cambodian villages in Pailin province were followed for 1 year at three-monthly intervals. A cohort of adult par-
ticipants found initially to have asymptomatic malaria parasitaemia was followed monthly over the same period.
Results: The initial cross sectional survey in June 2013 (M0) of 1447 asymptomatic residents found that 32 (2.2 %) 
had Plasmodium falciparum, 48 (3.3 %) had P. vivax, 4 (0.3 %) had mixed infections and in 142/1447 (9.8 %) malaria 
was detected but there was insufficient DNA to identify the species (Plasmodium. species). Polymorphisms in the 
‘K13-propeller’ associated with reduced susceptibility to artemisinin derivatives (C580Y) were found in 17/32 (51 %) P. 
falciparum strains. Monthly follow-up without treatment of 24 adult participants with asymptomatic mono or mixed 
P. falciparum infections found that 3/24 (13 %) remained parasitaemic for 2–4 months, whereas the remaining 21/24 
(87 %) participants had cleared their parasitaemia after 1 month. In contrast, 12/34 (35 %) adult participants with P. 
vivax mono-infection at M0 had malaria parasites (P. vivax or P. sp.) during four or more of the following 11 monthly 
surveys.
Conclusions: This longitudinal survey in a low transmission setting shows limited duration of P. falciparum carriage, 
but prolonged carriage of P. vivax infections. Radical treatment of P. vivax infections by 8-aminoquinoline regimens 
may be required to eliminate all malaria from Cambodia.
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Background
Deforestation and standard malaria control efforts 
including early, appropriate case management and dis-
tribution of insecticide-treated bed nets have reduced 
malaria prevalence to historically low levels in much of 
Western Cambodia. Unfortunately these control meas-
ures have failed to contain the emergence of anti-malarial 
drug resistant strains of Plasmodium falciparum in an 
expanding geographical area [1, 2]. In areas with very low 
malaria transmission the large majority of malaria infec-
tions were thought to be symptomatic and hence acces-
sible to passive detection and curative treatment [3]. Yet 
malaria has historically been difficult to eliminate even 
when most symptomatic patients received highly effec-
tive anti-malarial treatments. Symptomatic infections as 
a sole source of transmission cannot explain the virtual 
disappearance of malaria cases each year during the cool 
dry season and prompt return with the onset of rains. 
A significant sub-patent reservoir of P. falciparum car-
riers does explain both the epidemiology of malaria in 
these areas of seasonal malaria and why the current con-
trol and containment activities fail to contain resistant 
malaria [4, 5]. To understand and eliminate such a reser-
voir it is not only important to understand the prevalence 
at any one point in time but also the duration of individ-
ual infections.
Apparently healthy people who migrate to regions 
without malaria transmission and later give blood 
donations can remain infected asymptomatically with 
P. falciparum for up to 13  years [6]. Information on 
the distribution of persistent infections usually comes 
from cohort studies. Observational studies of untreated 
malaria patients were not uncommon during the last cen-
tury. Lowe followed 16 people with untreated malaria 
in India 1934 [7]. Hill and co-workers followed 22 chil-
dren with falciparum, malariae and/or vivax infections 
at weekly intervals during 1937 and 1938 in Aguas de 
Moura, Portugal who were only treated if symptomatic 
[8]. Earle et al. [9] followed 76 mostly untreated children 
in weekly intervals in Puerto Rico in 1939. McGregor and 
co-workers [10] studied falciparum infected, untreated 
children in The Gambia during the 1950s. Bruce-Chwatt 
[11] reported a cohort study of a group of West African 
adults in 1963. Bruce et  al. [12] reported a study con-
ducted in 1992 in which 70 people from a single village 
in Papua New Guinea (PNG) were sampled for up to 
61 days. The advent of PCR based molecular diagnostics 
on low volume capillary blood spots allowed the docu-
mentation of persistent low-density P. falciparum infec-
tions in Sudan over more extended periods [8]. In 1997, 
a cohort of 43 recently malaria-infected Sudanese, aged 
from 9 to 53, agreed to donate fortnightly blood samples 
for the next 9  months. Of the 43 individuals, 16 (37  %) 
were found to maintain chronic P. falciparum infections 
for the follow-up period of 9  months. Together these 
studies demonstrated that individual patients can carry P. 
falciparum infections for weeks to years.
These historical field studies in endemic countries 
are not only limited by the detection threshold of light 
microscopy (the exception being the study in Sudan) 
but also by uncertainty regarding re-infections. The risk 
of reinfection is much reduced in very low or no trans-
mission areas. A substantial contribution to the current 
understanding of the natural history of Plasmodium 
infections comes from the malaria therapy of neuro-
syphilis. In well-documented treatments patients with 
neurosyphilis were infected with P. falciparum or P. vivax 
in South Carolina and Georgia, USA during the period 
1940–1963 [13, 14]. Plasmodium falciparum infections 
persisted (by microscopy) for a mean of 222  days the 
longest being 480 days [15]. Malaria naïve patients who 
received sporozoite-induced vivax infections and no 
anti-malarial therapy were found to have waves of para-
sitaemia during the follow-up period of 108 days [16]. In 
contrast to P. falciparum infections the dynamics of vivax 
infections are complicated by the liver reservoir of P. 
vivax hypnozoites, which cause periodic relapses and so 
contribute to the chronicity of parasitaemia [14].
The development of high volume ultrasensitive qPCR 
(uPCR) allows as few as 22 parasites/mL to be measured 
accurately compared to  ~1000 parasites/mL using con-
ventional low volume PCR methods [17]. Using uPCR 
for the detection of parasitaemia, the entire population 
of three Cambodian villages in Pailin province were fol-




Pailin is an agricultural province adjacent to the Thailand 
border in western Cambodia. The villages are farming 
communities, which grow cash crops and fruit. Nearby 
forests are used as a source of plants and fruit, small 
game, bamboo and wood. Containment efforts in Cam-
bodia have resulted in a marked decline in the incidence 
of clinical malaria over the last decade. Between 2004 
and 2013 a 145-fold reduction in P. falciparum cases and 
a 4.8-fold reduction in P. vivax cases was observed [18]. 
Malaria control in Pailin has been based on case manage-
ment by village health workers (VHW) or village malaria 
workers (VMW) and the distribution of long-lasting 
insecticide-treated bed nets (LLIN). There has been sub-
stantial replacement of forest by agriculture and rubber 
plantations, which could have contributed to the reduc-
tion in malaria transmission. Historically P. falciparum 
has been the dominant Plasmodium species causing 
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malaria but more recently P. vivax infection has become 
predominant [18]. Malaria transmission is low and sea-
sonal with entomological inoculation rates below one 
infectious bite/person/year [19, 20].
Western Cambodia has been the epicentre for the 
emergence of P. falciparum strains resistant against a 
range of anti-malarial drugs including chloroquine, sul-
fadoxine/pyrimethamine, artemisinins and piperaquine 
[21–26]. The first-line treatment for falciparum malaria 
through December 2013, the first 6 months of the study, 
was atovaquone/proguanil (Malarone©) which tempo-
rarily replaced artesunate–mefloquine, and was itself 
replaced in January 2014 with dihydroartemisinin/
piperaquine (DHA/piperaquine) [27]. Vivax malaria is 
treated with a schizontocidal drug which is usually an 
artemisinin combination therapy (ACT). Radical cure 
for vivax malaria with primaquine after G6PD testing is 
recommended but as G6PD tests are unavailable this is 
seldom used. In the Pailin area the primary health care 
providers for febrile illness are the VMWs who are super-
vised by the local government health centre. The VMWs 
stock rapid diagnostic tests (RDTs) and ACT. Primary 
healthcare from VMWs is intended to be available 24 h 
a day and is free. Patients with a diagnosis other than 
malaria are referred to or go directly to a local health 
centre, which is approximately 6 km from the study vil-
lages and serves other villages in the surrounding area. 
Those who require hospitalization travel to the Pailin 
Referral Hospital, which is roughly 30 km from the study 
site. Malaria treatment by the private sector is prohibited 
in Pailin but pharmacies and drug sellers do stock anti-
malarial drugs. In practice patients who believe that a 
malaria diagnosis is unlikely bypass the VMW.
In 2013, the Cambodian National Centre for Parasi-
tology, Entomology and Malaria Control (CNM) and 
Mahidol-Oxford Tropical Medicine Research Unit 
(MORU) formed a research team based in Pailin Referral 
Hospital to investigate the prevalence of subclinical para-
sitaemia. Three study villages were selected for participa-
tion in the study on the basis of high relative incidence of 
clinical falciparum malaria in the village malaria worker 
records.
Study procedures
In each village, a study committee was formed consist-
ing of village leaders, VMWs, and volunteers. The com-
mittee assisted the study team in organizing the study 
and in engaging and mobilising the community. All 
households were geo-referenced by GPS and given a 
unique household number. In a census in April 2013 all 
residents were recorded, assigned a unique identifica-
tion number and linked to a household number. In June 
2013, the first of five cross-sectional surveys (M0) was 
conducted, followed by further surveys in October 2013 
(M3), January 2014 (M6), April 2014 (M9) and June 2014 
(M11). Before each survey, the population residing in the 
village at the time, including temporary residents and 
migrants were invited to participate. People moving into 
the villages between surveys for more than 2 weeks were 
included in the study.
Individual informed consent was obtained from adults 
and from parents or guardians of children aged less than 
16  years. Information on demographics and household 
relationships were collected with a brief history of recent 
illness and travel. The tympanic temperature, weight, 
and height of all participants were measured. A venous 
blood sample (3 mL) from all individuals aged ≥5 years 
was collected in EDTA tubes, or 500  µL from chil-
dren aged  ≥6  months to 5  years. Participants with 
fever ≥37.5 °C were tested for malaria by rapid diagnostic 
test (Healgen malaria P. falciparum/Pan one-step RDT, 
Zhejiang Orient Biotech, China), and if positive were 
treated according to national guidelines [27].
Blood samples were stored on wet ice in the field and 
then transported within 9 h to a local laboratory in Pailin. 
Blood was centrifuged at 1500g for 10 min (Heraeus lab-
fuge 400) to separate plasma and buffy coat from packed 
red blood cells (pRBC). 500 µL pRBC samples for uPCR 
analysis were then frozen and stored at −80 °C. Batches 
of frozen samples were transported monthly on dry ice to 
the Molecular Tropical Medicine laboratory in Bangkok, 
Thailand for uPCR analysis as described previously [17].
Participants aged 16  years and older who were found 
to be parasitaemic by uPCR were informed of their status 
and invited to join a study cohort. Cohort members were 
tested monthly for parasitaemia. The first survey (M1) 
was in August 2013. Subsequent cohort surveys were 
conducted in September 2013 (M2), November 2013 
(M4), December 2013 (M5), February 2014 (M7), March 
2014 (M8) and May 2014 (M10). After the study closed, 
the local health centre provided free treatment according 
to national guidelines to all participants with persistent 
parasitaemia.
Laboratory methods
A detailed description, evaluation and validation of the 
high-volume uPCR methodology has been reported pre-
viously [17]. Briefly, the DNA template for detection and 
quantification of Plasmodium by PCR is purified from 
thawed pRBCs. The presence of malaria parasites and 
an estimate of the parasite numbers (genomes) in each 
sample are assessed by an absolute quantitative real-
time PCR method using primers targeting the gene for 
18S rRNA. A Quanti-Tect Multiplex PCR No ROX® Kit 
(QIAGEN, Germany) was used for this purpose with the 
PCR reaction mixture and the cycling conditions as per 
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manufacturer’s instructions. The probes used in the assay 
have been validated and are highly specific for Plasmo-
dium species [28]. The lower limit of detection of this 
method is 22 parasites/mL of whole blood [29]. For sam-
ples containing parasite DNA by uPCR analysis, Plas-
modium species detection was attempted using nested 
PCR protocols specific to P. falciparum (microsatellite 
marker Pk2), P. vivax (microsatellite marker 3.502) and 
P. malariae (18 s rRNA) as described previously [28, 30, 
31]. Samples for which Plasmodium species could not be 
determined were reported as Plasmodium species.
To detect polymorphisms associated with reduced sus-
ceptibility to artemisinin derivatives the open-reading 
frame of the PF3D7_1343700 kelch propeller domain 
was amplified using a nested PCR protocol [1, 32]. Puri-
fied PCR products were sequenced at Macrogen, Repub-
lic of Korea and analysed using BioEdit version 7.1.3.0. 
using the 3D7 kelch13 sequence as reference (Acces-
sion: XM_001350122.1). The definition of single nucleo-
tide polymorphisms (SNPs) was based on analytical 
approaches described previously [1, 33].
Data management and statistical analyses
Data were collected on smartphones using ODK software 
[34] and then managed by importing into OpenClinica 
[35].
Definitions
a. At each quarterly survey, the numbers of residents 
and participants in the study villages changed as resi-
dents moved away, refused to participate, travelled, 
died, joined the village, were born or returned from 
travel. Reasons for non-participation were catego-
rized as: moved away for more than 1 month, short 
travel (defined here as less than 1  month), refusal, 
unable, not known, or ineligible. Because the cat-
egories short travel, unable to attend and refusal can 
overlap, they were combined.
b. The ineligible category included the severely ill, chil-
dren less than 6  months of age or participants who 
did not consent to a blood draw.
c. A participant was defined as an individual who par-
ticipated in the survey and agreed to give a blood 
sample.
d. Coverage was estimated as the percentage of resi-
dents who provided a blood sample for uPCR analy-
sis (numerator) divided by the number of invited res-
idents (denominator). The invited residents represent 
the de facto population in the village at the time of 
the respective survey.
e. Cohort participants were those aged 16  years and 
older who were found to be parasitaemic at M0 and 
followed monthly during the study period.
f. Carriers were a subgroup of the cohort defined for 
the purposes of this study as being parasitaemic dur-
ing four or more surveys. The definition was derived 
from the frequency distribution. Carriers represent 
the top quartile of the frequency distribution, 75 % of 
the cohort had fewer than four episodes.
To determine independent predictors for parasitaemia 
within the adult cohort, a logistic regression model was 
developed wherein the order of observations for each 
subject was considered by month (M0–11). Each member 
of the cohort was fitted as a random effect to adjust for 
any dependence of repeated events. Risk factors investi-
gated included, village, sex, occupation (farmer or not), 
and age (continuous). Time-varying risk factors (which 
were asked at each survey) included self-reported history 
of fever, self-reported history of malaria, travel (0/1), and 
bed net use (0/1). Potential interactions between covari-
ates were also explored. To ensure good model fit, the 
quadrature approximation used in the random-effects 
estimators was checked. A p value  <0.05 was consid-
ered statistically significant. All analyses were performed 
using Stata, version 13 (StataCorp, College Station, TX, 
USA).
Additional data sources
Daily rainfall and maximum/minimum temperature data 
were collected from the Pailin Meteorological Office. 
Information on clinical (symptomatic) malaria episodes 
were collected by VMW, VHW and primary health cen-
tres for 2013–14.
Ethics approval
The study was approved by the Cambodian National Eth-
ics Committee for Health Research (0029 NECHR, dated 
4th March 2013) and the Oxford Tropical Research Eth-
ics Committee (1015-13, dated 29th April 2013).
Results
Study population
Details of 1758 residents were collected in the April 2013 
census. Between June 2013 and June 2014 five surveys 
were conducted targeting all village residents. By the 
end of the surveillance period in June 2014 the number 
of residents who had been registered in the villages had 
increased to 2330. Over the same period many people 
had moved out of the villages, hence the number of peo-
ple invited to the final M11 survey (1501) was similar to 
the number invited to the M0 survey (1540). Coverage in 
prevalence surveys ranged from 80–94 % of those present 
in the village at the time. The numbers of residents who 
were invited to participate, who participated or who did 
not participate are shown in Table 1.
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Participant characteristics
Data were collected on 2330 people residing during the 
whole or part of the study period in three participating 
villages. The median age was 22 years (range 3 months to 
83 years). Overall, 52 % of residents were male, 39 % were 
children <16 years old and 15 % were ≤5 years old. There 
were 419 households with a median household size of 
five people. Most houses consisted of a large single room 
used for both daytime activities and for sleeping. More 
than 97 % of permanent villagers reported sleeping under 
a bed net at the time of each survey. The median time of 
residence was 6 years (range 1 month to 38 years). Demo-
graphic characteristics of the 2330 participants by uPCR 
result are shown in Table 2.
Seasonal distribution of parasitaemia
The seasonal distribution of P. falciparum, P. vivax 
and all Plasmodium infections, including infections 
in which the species could not be identified (P. species) 
are shown in Fig. 1. Based on uPCR in June 2013 (M0) 
32/1447 (2.2  %) residents had P. falciparum infections, 
48 (3.3  %) had P. vivax infections, 4 (0.3  %) had mixed 
infections, and 142 (9.8 %) had malaria infection but the 
species could not be identified. No species other than P. 
falciparum or P. vivax were identified. The P. falciparum 
malaria prevalence dropped below 1 % by October 2013 
(M3) and remained below 1 % during the following three 
surveys (M6, M9, M11). In contrast, P. vivax prevalence 
remained stable between 3 and 5  % during the study 
period. Overall the highest parasite prevalence (16 %; all 
species) was seen in June 2013 (early in the rainy season) 
and dropped to 5–7  % for the rest of the study period. 
Figure  2a–c illustrates, the relation between parasite 
prevalence estimated using uPCR, clinical cases diag-
nosed by VMW, VHW and primary health centres and 
meteorological variables. There was no detectable cor-
relation between Plasmodium prevalence and rainfall or 
temperature.
Resistance markers
The mutation C580Y in the PF3D7_1343700 kelch pro-
peller domain which is associated with reduced suscepti-
bility to artemisinin derivatives was found in 17/32 (51 %) 
P. falciparum strains. No other kelch polymorphisms 
were detected. The C580Y mutation was distributed 
heterogeneously between villages; it was found in 15/15 
(100 %) samples from PDB village but in only 2/17 (12 %) 
samples from KL village.
Cohort survey
136 villagers age 16 or older were found to be infected 
with P. falciparum, P. vivax, or P. species by uPCR in June 
2013 (M0); 24 were infected with P. falciparum, 34 with 
P. vivax and in the rest the Plasmodium species could not 
be identified (n = 78). These 136 villagers were followed 
monthly for the 12 months surveillance period from June 
2013 (M0) to June 2014 (M11). Of the 24 cohort members 
with mono or mixed P. falciparum infections at M0, three 
remained parasitaemic over 2–4 months, five were found 
have P. vivax parasitaemia during the follow-up period 
and four had Plasmodium infections in which the spe-
cies could not be determined. The persistence of P. fal-
ciparum infections is illustrated in Fig. 3. Figure 4 shows 
the 34 cohort members with P. vivax mono-infections at 
M0; 12/34 (35  %) who were parasitaemic with P. vivax 
or P. species in more than half of the following surveys. 
The Plasmodium species of 78 participants found to be 
parasitaemic on M0 could not be determined (Additional 
file  1: Figure S1). Three of those 78 participants with P. 
species infections at M0 were parasitaemic with either P. 
vivax or P. species in at least half of the following surveys.
The risk of being positive for malaria by uPCR was 
investigated in the adult cohort (n =  136). The odds of 
carrying subpatent parasites decreased over time (AOR 
0.82, 95 % CI 0.76–0.87). Being male and a self-reported 
history of malaria were the only two significant risk fac-
tors associated with a positive uPCR result (Table  3). 
Table 1 Assembly of study participants and coverage (see “Methods” section for definitions)
a  Includes all villagers who were not away from the village for more than 1 month
b  Short travel away for <1 month
c  Provided a blood sample









In-eligible Participatedc Coveraged (%)
M0 1758 218 1540 69 0 24 1447 94
M3 1992 469 1523 88 4 46 1385 91
M6 2125 573 1552 263 0 44 1245 80
M9 2230 845 1385 100 4 36 1245 90
M11 2330 829 1501 193 0 41 1266 84
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Overall, a subgroup of 37 of the 136 cohort members 
was parasitaemic during four or more monthly sur-
veys. Compared to other cohort members the carriers 
(Table 4) were significantly more likely to be male (26/37 
vs. 45/99, p = 0.010) and were slightly older (median age 
35 years) compared to 33 years in other cohort members 
Table 2 Demographics of participants by uPCR result
Numbers are frequency (%), unless otherwise specified
a  At least once during the study period
b  Column percentages
c  Military or police, own business, health worker, stays at home, retired or disabled, government staff, monk/nun, resort staff, NGO employee, teacher, village chief
Positivea % Negative % No uPCR result % Total %b p value
N 333 14.3 % 1818 78.0 % 179 7.68 % 2330 100 %
Sex
 Female 122 10.9 % 911 81.2 % 89 7.93 % 1122 48.2 %
 Male 211 17.5 % 907 75.1 % 90 7.45 % 1208 51.9 % <0.0001
 Age, years 
(median, 
range)
24 (7 months to 74 
years)
21 (6 months to 80 
years)
21 (3 months to 
83 years)




 Krachap Leu 130 15.6 % 635 76.2 % 68 8.16 % 833 35.8 %
 O Kting 42 9.61 % 358 81.9 % 37 8.47 % 437 18.8 %
 Phnom Dam-
bang
161 15.2 % 825 77.8 % 74 6.98 % 1060 45.5 % 0.029
Occupation
 Farms own 
land
142 19.2 % 539 72.7 % 60 8.10 % 741 31.8 %
 Hired farm 
labourer
66 10.8 % 512 83.9 % 32 5.25 % 610 26.2 %
 Child or stu-
dent
116 13.1 % 700 79.1 % 69 7.80 % 885 38.0 %
 Otherc 9 9.57 % 67 71.3 % 18 19.2 % 94 4.03 % <0.0001
Fig. 1 Parasite prevalence at 3-monthly surveys of the entire village
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(p  =  0.373). All carriers were farmers by occupation 
(compared with 92/99 among non-carriers, p = 0.189).
Sub patent parasite densities
The individual parasite densities of the 37 carriers over 
the 12  months study period are shown in Additional 
file 1: Figure S2. Over the 12 months study periods par-
asitaemias were cleared between zero and four times 
(mean 3.3, standard deviation 1.3) and recurred between 
0 and 4 times (mean 3.1, SD 1.2). Parasitaemia episodes 
lasted between 0 and 12 months (mean 2.8, SD 2.1). The 
periods of clearance in this cohort lasted between 1 and 
8 months (mean 2.1, SD 1.8). In three carriers (KH10807, 
KH30276, KH21144; see Additional file  1: Figure S2), 
all male, parasites were detected in 12 sequential vis-
its (Fig.  5). The three persistent carriers controlled the 
parasite densities within 2–4 logs (log parasites/mL). Two 
of the three carriers (KH10807, KH30276) had a spo-
radic co-infection (PV+PF) during the study period. Fre-
quently parasites became undetectable during the study 
period either to stay undetectable during the remainder 
of the study period or to reappear at a later stage.
Discussion
The availability of a new diagnostic tool, highly sensitive 
PCR (uPCR) provides a new perspective on the epidemi-
ology of malaria, allowing characterization of the subclin-
ical and submicroscopic Plasmodium reservoir [17]. The 
limit of parasite detection in this study is approximately 
50 times lower than with the extensively employed capil-
lary blood filter paper based PCR methods [36]. This is 
sufficient to identify the majority of infected individuals 
Fig. 2 a, b, and c represent the prevalence of Plasmodium falciparum or mixed infections (a), Plasmodium vivax or mixed infections (b), and all spe-
cies, including Plasmodium species which could not be determined (c). The figures represent a composite of uPCR data from cross-sectional surveys, 
clinical data collected by village malaria workers, and meteorological data collected by the Department of Meteorology, Ministry of Water Resources 
and Meteorology, Cambodia. The percentage of specimens found to be positive by uPCR is indicate by diamonds. The ambient min/max tempera-
ture range is indicated by dots. The daily rainfall in mm is shown as a blue line. uPCR data were collected during the study period June 2013 and 
June 2014 indicated by the red arrow. The clinical and meteorological data were collected between January 2013 and December 2014. Information 
on malaria episodes were collected by village malaria (VMW), mobile malaria workers (MMW) and primary health centres for 2013–14
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[37]. Approximately four times more asymptomatic 
infected individuals were identified in these studies with 
this method than with conventional microscopy or rapid 
diagnostic tests [36].
The study was conducted in an area of low seasonal 
malaria transmission at a time of strengthening malaria 
control and environmental change. The prevalence of P. 
falciparum infections was already low and declined fur-
ther while the prevalence of P. vivax remained relatively 
stable. During the 1 year of follow up no obvious season-
ality was detected. This disparity between the incidence 
of malaria and the prevalence of asymptomatic para-
sitaemia is also seen in areas of much higher transmis-
sion, such as the sub-Sahel, where there is also marked 
seasonality in the incidence of clinical malaria yet much 
less variation in asymptomatic carriage [38, 39]. This 
illustrates the importance of asymptomatic malaria as the 
transmission reservoir infecting increasing numbers of 
anopheline vectors, as vectorial capacity rises abruptly at 
the beginning of the rainy season.
Ongoing molecular studies strongly suggest that the 
observed low densities of parasites are alive as they are 
expressing RNA. There is debate whether low-density 
parasitaemias are transmissible [4]. Several studies from 
sub-Saharan Africa, Asia, South America, and Pacific 
Islands have demonstrated that submicroscopic falci-
parum as well as vivax infections can be transmitted to 
mosquitoes [40–47]. These discussions usually revolve 
around the transmission potential at the time of sam-
pling, but would be more epidemiologically relevant if 
they considered the transmission potential of an indi-
vidual over time. An individual may have a low-density 
Fig. 3 The persistence and transitions of Plasmodium falciparum infections in an adult cohort (ordered by number of episodes)
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non-transmissible infection on 1 day, but later densities 
may rise and infect biting anopheline mosquitoes. A 
recent study conducted in Papua New Guinea detected P. 
falciparum in 19 % and P. vivax in 13 % of 2083 samples 
using conventional PCR. Gametocytes could be detected 
in 60  % of P. falciparum-positive and 51  % of P. vivax-
positive samples by detection of pfs25 and pvs25mRNA 
transcripts [48]. Gametocytaemia is probably present in 
all chronic infections but densities fluctuate out of phase 
with asexual parasitaemia waves.
A cohort of adults with Plasmodium parasitaemia at 
the time of the first survey was followed over a 12 months 
period in monthly intervals. In this cohort P. falciparum 
infections were short lived; three participants remained 
Fig. 4 The persistence and transitions of Plasmodium vivax infections in an adult cohort (ordered by number of episodes)
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infected for 2–4 months. By contrast a third of the par-
ticipants with P. vivax infections remained parasitaemic 
for more than half of the following surveys. Three dif-
ferent patterns of persistence were observed. First, the 
infection could be cleared within the first months of the 
study period and did not reoccur. Second, no parasitae-
mias were detected during 1 or 2 months, only to reap-
pear during subsequent months. Third, in a minority of 
participants persistent parasitaemias could be detected 
during each survey. Changes in genotype profiles over 
time within individual participants are currently under 
investigation.
In participants who control their infections relatively 
well, as illustrated by three participants who remained 
parasitaemic and asymptomatic during 12 surveys, the 
parasite densities remain low and the oscillation ampli-
tude was less than one hundred fold. Oscillating parasite 
densities have been described previously in vivax as well 
as falciparum malaria therapy for patients with neuro-
syphilis [14, 49] and a more recent study conducted in an 
area of PNG with very high P. falciparum, P. vivax and 
P. malariae prevalence [12]. In PNG 70 asymptomatic 
villagers were sampled every third day for a period of 
61 days. Infections often lasted for several weeks in young 
children but generally for only a few days in adults. The 
periodicity of infections observed in PNG was attributed 
to sequestration of synchronously replicating P. falcipa-
rum parasites as reported elsewhere [50]. Periodic oscil-
lation of P. falciparum densities has also been reported in 
asymptomatic children in rural Tanzania sampled daily 
for 14 days [51]. It seems more likely that parasite mul-
tiplication varies over time, controlled by mechanisms 
such as antibody responses to variant surface antigens 
[52, 53].
The decline in P. falciparum prevalence observed in 
this study could be short-lived. Half of the P. falciparum 
strains had a mutation (C580Y) in the gene coding for the 
K-13 propeller which is associated with reduced suscep-
tibility to artemisinin derivatives. Artemisinins used in 
combination with a partner drug are the global first line 
treatment for uncomplicated malaria. In the presence of 
artemisinin resistance P. falciparum strains with reduced 
susceptibility of the partner drug emerge and spread rap-
idly [22, 23, 54]. The complete replacement of wild type 
with C580Y mutant strains in one village suggests a need 
for urgent action to interrupt the transmission of the 
remaining P. falciparum strains [55, 56].
The study also shows a shift in malaria burden from P. 
falciparum to P. vivax which is increasingly responsible 
for malaria related morbidity and mortality in the region. 
The radical cure of patients with persistent vivax infec-
tions has a high priority not only for the benefit of the 
patient but to minimize the transmission of this infection. 
Radical cure of vivax infections requires use of 8-ami-
noquinolines such as primaquine. Fear of haemolysis in 
Table 3 Comparison of  variables associated with  qPCR 
positivity in cohort members (n = 136)
a  Includes only variables that were significant in univariate analysis
N OR_
crude
95 % CI OR_adja 95 % CI
Village
 KL 60 Ref.
 OK 17 0.99 0.42–2.35
 PDB 59 0.90 0.50–1.63
Male 136 2.07 1.21–3.56 2.38 1.12–5.05
Age (median years; 
range)
136 1.00 0.98–1.02
Farmer 136 2.72 0.76–9.70
Bednet use (n = 124) 136 0.53 0.13–2.08
History of fever 136 1.63 0.60–4.42
History of malaria 136 99.0 32.1–306 92.1 29.3–290
Travel 131 3.88 1.60–9.41 2.63 0.92–7.56
Village agea
 KL 60 Ref.
 OK 17 0.98 0.91–1.05
 PDB 59 0.98 0.94–1.03
Sex travela 131 2.27 0.66–7.85
Farmer agea 136 1.01 0.92–1.12
Table 4 Comparison of cohort members who were prolonged parasite carriers and non-carriers
* 2 df
Non-carriers % Carriers % Total p value
N 99 73 % 37 27 % 136
Village
 KL 43 71.7 17 28.3 60
 OK 11 64.7 6 35.3 17
 PDB 45 76.3 14 23.7 59 0.62*
Male 45 45.5 % 26 70.3 % 71 0.010
Age (median years; range) 33 16–72 35 16–65 34 0.37
Farmer 92 92.9 % 37 100 % 129 0.19
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G6PD deficient patients and the absence of a practical, 
low-cost rapid diagnostic test to diagnose G6PD defi-
ciency have so far obstructed the wider use of this class 
of drugs.
Conclusion
Malaria control in western Cambodia has been highly 
successful resulting in a more than a 100-fold reduc-
tion in P. falciparum cases and a more modest fivefold 
reduction in P. vivax cases in the study sites. The slower 
reduction in P. vivax than in P. falciparum transmission is 
likely due to the hypnozoite reservoir, which is resistant 
to current control measures. A new technology, uPCR, 
provides insights into the dynamics of asymptomatic, 
subpatent Plasmodium infections. The findings suggest 
that the elimination of submicroscopic reservoirs is an 
essential step in the eradication of malaria. The inclu-
sion of hypnozoiticidal drugs such as primaquine in the 
first-line treatment of P. vivax malaria will be necessary 
to accelerate the elimination of vivax malaria.
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